152 related articles for article (PubMed ID: 17597266)
21. Critical role of perforin-dependent CD8+ T cell immunity for rapid protective vaccination in a murine model for human smallpox.
Kremer M; Suezer Y; Volz A; Frenz T; Majzoub M; Hanschmann KM; Lehmann MH; Kalinke U; Sutter G
PLoS Pathog; 2012; 8(3):e1002557. PubMed ID: 22396645
[TBL] [Abstract][Full Text] [Related]
22. Rapid spreading and immune evasion by vaccinia virus.
Smith GL
Adv Exp Med Biol; 2014; 808():65-76. PubMed ID: 24595611
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of modified vaccinia virus Ankara as an alternative vaccine against smallpox in chronically HIV type 1-infected individuals undergoing HAART.
Cosma A; Nagaraj R; Staib C; Diemer C; Wopfner F; Schätzl H; Busch DH; Sutter G; Goebel FD; Erfle V
AIDS Res Hum Retroviruses; 2007 Jun; 23(6):782-93. PubMed ID: 17604541
[TBL] [Abstract][Full Text] [Related]
24. Determination of immunity to vaccinia virus by using diluted inactivated vaccinia vaccine solution for skin testing.
Somekh E; Smetana Z; Tanay A; Dalal I; Babai I; Mendelson E
Vaccine; 2004 Dec; 23(3):321-4. PubMed ID: 15530675
[TBL] [Abstract][Full Text] [Related]
25. Cutaneous responses to vaccinia in individuals with previous smallpox vaccination.
Simpson EL; Hercher M; Hammarlund EK; Lewis MW; Slifka MK; Hanifin JM
J Am Acad Dermatol; 2007 Sep; 57(3):442-4. PubMed ID: 17560685
[TBL] [Abstract][Full Text] [Related]
26. Response to smallpox vaccine in persons immunized in the distant past.
Frey SE; Newman FK; Yan L; Lottenbach KR; Belshe RB
JAMA; 2003 Jun; 289(24):3295-9. PubMed ID: 12824212
[TBL] [Abstract][Full Text] [Related]
27. An open-label, single arm, phase III clinical study to evaluate the efficacy and safety of CJ smallpox vaccine in previously vaccinated healthy adults.
Kim NH; Kang YM; Kim G; Choe PG; Song JS; Lee KH; Seong BL; Park WB; Kim NJ; Oh MD
Vaccine; 2013 Oct; 31(45):5239-42. PubMed ID: 24021303
[TBL] [Abstract][Full Text] [Related]
28. Postexposure immunization with modified vaccinia virus Ankara or conventional Lister vaccine provides solid protection in a murine model of human smallpox.
Paran N; Suezer Y; Lustig S; Israely T; Schwantes A; Melamed S; Katz L; Preuss T; Hanschmann KM; Kalinke U; Erez N; Levin R; Velan B; Löwer J; Shafferman A; Sutter G
J Infect Dis; 2009 Jan; 199(1):39-48. PubMed ID: 19012492
[TBL] [Abstract][Full Text] [Related]
29. Monitoring of human immunological responses to vaccinia virus.
Harrop R; Ryan MG; Golding H; Redchenko I; Carroll MW
Methods Mol Biol; 2004; 269():243-66. PubMed ID: 15114020
[TBL] [Abstract][Full Text] [Related]
30. Modified vaccinia Ankara: potential as an alternative smallpox vaccine.
McCurdy LH; Larkin BD; Martin JE; Graham BS
Clin Infect Dis; 2004 Jun; 38(12):1749-53. PubMed ID: 15227622
[TBL] [Abstract][Full Text] [Related]
31. Safety and immunogenicity of IMVAMUNE® smallpox vaccine using different strategies for a post event scenario.
Frey SE; Winokur PL; Salata RA; El-Kamary SS; Turley CB; Walter EB; Hay CM; Newman FK; Hill HR; Zhang Y; Chaplin P; Tary-Lehmann M; Belshe RB
Vaccine; 2013 Jun; 31(29):3025-33. PubMed ID: 23664987
[TBL] [Abstract][Full Text] [Related]
32. Prediction of residual immunity to smallpox, by means of an intradermal skin test with inactivated vaccinia virus.
Kim SH; Bang JW; Park KH; Park WB; Kim HB; Kim NJ; Jee Y; Cho H; Oh MD; Choe KW
J Infect Dis; 2006 Aug; 194(3):377-84. PubMed ID: 16826487
[TBL] [Abstract][Full Text] [Related]
33. Persisting humoral antiviral immunity within the Japanese population after the discontinuation in 1976 of routine smallpox vaccinations.
Hatakeyama S; Moriya K; Saijo M; Morisawa Y; Kurane I; Koike K; Kimura S; Morikawa S
Clin Diagn Lab Immunol; 2005 Apr; 12(4):520-4. PubMed ID: 15817760
[TBL] [Abstract][Full Text] [Related]
34. Bioterrorism. Smallpox vaccinations: how much protection remains?
Cohen J
Science; 2001 Nov; 294(5544):985. PubMed ID: 11691969
[No Abstract] [Full Text] [Related]
35. Third-generation smallpox vaccines: challenges in the absence of clinical smallpox.
Meseda CA; Weir JP
Future Microbiol; 2010 Sep; 5(9):1367-82. PubMed ID: 20860482
[TBL] [Abstract][Full Text] [Related]
36. Comparison of the safety and immunogenicity of ACAM1000, ACAM2000 and Dryvax in healthy vaccinia-naive adults.
Frey SE; Newman FK; Kennedy JS; Ennis F; Abate G; Hoft DF; Monath TP
Vaccine; 2009 Mar; 27(10):1637-44. PubMed ID: 19071184
[TBL] [Abstract][Full Text] [Related]
37. Protective CD8+ T cell memory without help.
Fang M; Sigal LJ
Oncotarget; 2015 Oct; 6(30):28529-30. PubMed ID: 26356572
[No Abstract] [Full Text] [Related]
38. Smallpox vaccination and patients with human immunodeficiency virus infection or acquired immunodeficiency syndrome.
Bartlett JG
Clin Infect Dis; 2003 Feb; 36(4):468-71. PubMed ID: 12567305
[TBL] [Abstract][Full Text] [Related]
39. Human antibody responses to the polyclonal Dryvax vaccine for smallpox prevention can be distinguished from responses to the monoclonal replacement vaccine ACAM2000.
Pugh C; Keasey S; Korman L; Pittman PR; Ulrich RG
Clin Vaccine Immunol; 2014 Jun; 21(6):877-85. PubMed ID: 24759651
[TBL] [Abstract][Full Text] [Related]
40. Protection against lethal vaccinia virus challenge in HLA-A2 transgenic mice by immunization with a single CD8+ T-cell peptide epitope of vaccinia and variola viruses.
Snyder JT; Belyakov IM; Dzutsev A; Lemonnier F; Berzofsky JA
J Virol; 2004 Jul; 78(13):7052-60. PubMed ID: 15194781
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
